December 2012 was a time of great promise for some leukemia patients. It was just under a year ago that the FDA approved Ariad Pharmaceuticals’ drug Iclusig for clinical trials to treat two rare forms of leukemia.
10 Months Later the Hope Was Halted When Iclusig Studies Stopped
On October 31, 2013 Ariad Pharmaceuticals announced that the FDA had asked the drug manufacturer to stop marketing Iclusig. Here’s what happened in the weeks leading up this announcement:
- On October 9, 2013 Ariad Pharmaceuticals announced a higher rate of blood clots among leukemia patients who took Iclusig.
- The FDA asked Ariad to stop taking new patients for clinical trials of Iclusig.
- On October 18, 2013 Ariad announced that it was ending late-stage trials of the drug because of the increased risk of blood clots.
- On October 30, 2013 the FDA asked Ariad to stop marketing Iclusig because 48% of patients enrolled in early-stage trials and 24% of patients enrolled in mid-stage trials suffered from serious side effects including heart attacks, strokes, and death.
Now, Iclusig studies are stopped and the future of Iclusig is currently unclear. However, what is more important than the future of the drug is the future of the patients, and families, who have been affected by Iclusig’s side effects.
Call a Kentucky Iclusig Lawyer If You’ve Been Hurt or a Loved One’s Been Killed
If you have been hurt or a loved one has been killed by Iclusig then we encourage you to find out more about your legal rights and possible recovery from an experienced Kentucky pharmaceutical injury lawyer. Please call us today at 800.634.8767 or 502.210.8942 to schedule a FREE consultation.